Abstract
Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug Administration approvals and treatment guidelines in esophagogastric cancer, including the impact of location, stage, histology, human epidermal growth factor receptor 2 status, and PD-(L)1 expression on these guidelines. The role of immunotherapy in the locally advanced and metastatic setting is constantly expanding. Over the next few years, the many ongoing trials exploring immunotherapy are anticipated to bring new treatment regimens into the frontline setting with the potential to improve survival in patients with advanced disease.
© 2022 by American Society of Clinical Oncology
Conception and design: Sunita Patruni, Fatima Fayyaz, Daniel A. King
Administrative support: Tony Phillip
Collection and assembly of data: Sunita Patruni, Fatima Fayyaz, Daniel A. King
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Tony Phillip
Consulting or Advisory Role: Foundation Medicine, Daiichi Sankyo/Astra Zeneca, Deciphera
Daniel A. King
Stock and Other Ownership Interests: Illumina
Honoraria: Skysis, Ipsen, Omni Health
No other potential conflicts of interest were reported.
Comments (0)